A summary of selected DF/Net Research projects is presented below:
DF/Net has been working with IPM since 2007 on over sixteen microbicide studies, including the current large-scale IPM 027 clinical trial, The Ring Study. The Ring Study is designed to determine whether a monthly vaginal ring that delivers the ARV drug dapivirine helps prevent HIV infection in women and is safe for long-term use. The first efficacy study of a vaginal ring for HIV prevention, The Ring Study is expected …Read More ›
DF/Net has been working with IDRI on Leishmaniasis vaccine studies since 2006. Leishmaniasis is a parasitic disease that occurs in 88 countries around the world. It has an estimated annual incidence of two million cases and a prevalence of 12 million cases. Visceral leishmaniasis, the most severe form of the disease, affects vital organs and has a high fatality rate if not treated. Cutaneous leishmaniasis, the most common form of …Read More ›
After the success of iPrEx, DF/Net continued working with the Gladstone Institute, providing the data management for iPrEx OLE. iPrEx OLE (Open Label Extension) is a continuation of the iPrEx study designed to provide additional information about the safety of PrEP and the behavior of people taking PrEP over a longer term. It is hoped that participants’ knowledge that Truvada PrEP provides some protection against HIV infection, and the fact that all HIV-negative participants in iPrEx OLE know that they are receiving Truvada PrEP and not a placebo, will lead to increased use of the study drug by participants in iPrEx OLE, and increased protection against HIV infection.
This is a randomized, blinded, placebo-controlled clinical trial to determine if daily oral co-formulated emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) decreases HIV-1 acquisition and has acceptable safety in initially HIV-1-uninfected men who are receiving standard prevention interventions.